

PTO/SB/08A (08-Qd

Approved for use through 07/51/2006. Oxfor 04/59/59/59

U.S. Patent and Trademan Office, U.S. DEPARTMENT OF COMMERCE
ork Reduction Act of 1995, no persons are required to respond to a collection of information unless to collection as valid Oxfor Oxfordina a valid Oxford Control furnity

The Application Number

The Ap

Complete if Known		
Application Number		
Filing Date	June 12, 2006	
First Named Inventor	Jamieson	
Art Unit	 	
Examiner Name	1.	
Attomey Docket Number		
	Application Number Filing Date First Named Inventor Art Unit Examiner Name	

Examiner Cite Rocument Number Publication Date Name of Patentee or Applicant of Cited Number-Kind Code^{2 (Fluore)} Publication Date Name of Patentee or Applicant of Cited Document Figures Appear

Examiner Initials*	Cite No. 1	Document Number Country Code ³ Number ⁴ Kind Code ⁵ (^(k kdown)	Publication Plate MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
		WO 03/066086	08/14-2003	KARSTEN		
						_
	-					H

Examiner
Signature

FXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw he through citation if not in conformance and not considered. Include copy of this forf, with next communication to applicant. Applicant's injury citation delignation number (optional). See Kinds
Codes of USPTO Patient Documents of sews upside ago or MPEP 901.04. Father Office that issued the document by the two-letter code (VMPO Standard
ST3). For Japanese patient documents, the inclusion of the year of the region of the Emperor must precede the self-in unuber of the patient forcument. Kind of socurement by the appropriate symbols as indicated on the document under VMPO Standard ST. 16 if possible. Applicant is to place a check mark

The intermination introducer interruption and interruption in the control of the

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08B (08-0)

Approved for use through 07/31/2006. Solve 885 of 50/4 U.S. Patent and Trademark Office; U.S. DEPARTHENT OF COMMYMICS approved Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains, a valid Controp/uniber

Attorney Docket Number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| (Use as many sheets as necessary)
| Sheet | 1 | of | 4

Con	nplete if Known
Application Number	
Filing Date	June 12, 2006
First Named Inventor	Jamieson
Art Unit	
Examiner Name	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include hame of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, r.f.; date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Alexander et al., 1976, "Subcellular localization of B apoprotein of plasma lipoproteins in lat liver. "J. Cell Biol. 69: 241-283	
		Antonny et al., 1997, "Activation of ADP-ribos/lation factor 1 GTPase- activating protein by phosphatidylcholine-derived diacylglycerols." J. Biol Chem, 272, 30848-30351	
		Asp et al., 2000, "ADP closylation factor 1 and its activation of phospholipase D are important for the assembly of very low density lipoproteins." 3. Biol Chem. 275, 26265-26292	
		Balsinde, 2002, "Roles of valous phospholipases A2 in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling." Biochem J. 364/695-702	
		Biederbick etal., 1995, "Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vaccoles." Eur. J. Cell Bio. 66: 3-14	
		Blanchette-Mackie etal. 1995, "Perilipin is located on the surface layer of intracellular lipid droplets in adipocytes." J. Lipid Res., 36: 1211-1226	
		Burnett et al., 2003 A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia." J Biol. Chem. 278, 13442-13452	
		Chernomordik, L., M. M. Kozlov, and J. Zimmerberg. 1995. "Lipids in biological membrane fusion." J. Membr. Biol. 146:1-14	
	*	Cul et al, 1995, "Expression of phosphatidylethanelamine N- methyltraniferase-2 in McArdle-RH7777 hepatoma ells inhibits the CDP- choline prthway for phosphatidylcholine biosynthesis via decreased gene expression of CTP:	
		Daleke 2003, "Regulation of transbilayer plasma membrane phospholipid asymmetry." J. Lipd Res, 44, 233-242	
		pashti et al., 2002, "The N-terminal 1000 residues of apolipopotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly." Biochemistry. 11, 6978-6987	
		DeLong et al., 1999, "Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway". J. Biol. Chem. 274: 29683-29688.	
		Fisher et al., 2001, "The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways." J. Biol. Chem. 276, 27855-27863	
		Fisher et al., 1998, "Apolipoprotein B metabolism in hypertriglyceridemic diabetic patients administered either a fish oil- or vegetable oil-enriched	Γ,

	diet." J. Lipid Res. 39: 388-401	7
	Fisher and Ginsberg, 2002, "Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins", J. Biol. Chem. 277,17377-17380	7
	Gusarova etal., 2003, "Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER.", J. Biol. Chem. 278:48051-48058	
	Harris, 1999, "n-3 fatty acids and human lipoprotein metabolism: an update." Lipids Suppl 34, S257-S258	
	Hebbachi and Gibbons, 2001, "Microsomal membrane-associated apoB is the direct precursor of secreted VLDL in primary cultures of set hebatocytes." 1. Lipid Res.42, 1609-1617;	
	Hsu & al., 2000, "Effect of n-3 fatty acids on the composition and binding properties of lipoproteins in hypertriglyceridemic patients." Am. J. Clin. Nutr. 71: 28-35	
	Ichimura et al., 2000, "A ubiquitin-like system mediates protein lipidation." Nature 408, 488-492	
*	Kabeya et al., 2000, *LC3, a mammalian homologue of yeast Apg8p, is localized in automagosome membranes after processing.", EMBO J. 19 (21): 5720-5728	
	Klionsky and Emr, 2000, "Cell biology - Aytophagy as a regulated pathway of cellular degradation," Science 290,1777-1721	-
	Kotkat etal., 1999, "Effect of dietary fish oil (active EPA-30) on liver phospholipids in young and aged rats." Comp Blochem. Physiol A Mol. Integr. Physiol 122, 283-289	
	Lang and Davis, 1990, "Fish oil fatty acids impair VLDL assembly and/or secretion by cultured rat hepatocytes." J. Lipid Res, 31, 2079-2086;	
	McLeod et al. 1996, "Apoliporotein B sequence requirements for hepatic very low density lipoprotein assembly. Evidence that hydrophobic sequences within apolipoprotein B48 mediate lipid recruitment." J. Biol Chem 271, 18445-18495	
	McLeod etal.,1994, "Grboxyl-terminal truncation impairs lipid recruitment by apolipoprotein B200 but does not affect exerction of the truncated apolipoprotein B-pontaining lipoproteins." 3. %iol. Chem. 269,2852-2862	
	Morrisett et al. Effects of Sirolimus on Plasma Lipids, Lipoproteins, and Fatty Acid Medibolism in Renal Transplant Patiens. 1 Lipid Res 43:1170-1180, 2002	
	Mizushima etal., 2003, "Role of the Apg12 conjugation system in mammakan autophagy." Int. J. Biochem. and Cell Biology 35,553-561	
	Mizushima etal.,2001, "Dissection of autophagosome formation using Apg5- deficient mouse embryonic stem cells." J. CellBiol., 152(4), 657-668	
	Murphy and Vance, 1999, "Mechanisms of lipid-body formation.", Trends Blochem. Sci. 24: 109- 115	
	Nestel et al., 1984, "Suppression by diets rich in fish oil of very low density lipoprotein production in man." J. Clin. Invest. 74: 82-89;	
	Nishimaki-Mogami et al, 2002, "Inhibition of phosphatidylcholine synthesis via the phosphatidylethanolamine methylation pathway impairs incorporation of bulk lipids into VLDL in cultured rat hepatocytes." J. Lipid Res. 43, 1035-1045	
	Noga et al, 2002, "An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins." J. Biol Chem, 277, 42358-42365	/
	Packard and Shepherd, 1997, "Lipoprotein heterogeneity and apolipoprotein B metabolism", Arterioscler. Thromb.Vasc.Biol. 17, 3542-3556	

		/
	Parks et al., 1989, "Fish oil decreases hepatic cholesteryl ester secretion but not apoB secretion in African green monkeys." J. Lipid Res. 30: 1535-1544	
1	Parks et al., 1990, "Effect of fish oil diet on hepatic lipid metabolism in nonhuman primates: lowering of secretion of hepatic triglyceride but not apoB. "J. Lipid Res. 31: 455-466	
	Phung etal., 1997, "Phospholnositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum." J. Biol Chem. 272,30693-30702	
	Reggiori and Klionsky 2002, "Autophagy in the eukaryotic cell." Eukaryot. Cell 1(1): 11-21	
	Rustaeus et al.,1999, "Assembly of very low density lipoprotein: a two-step process of apolipoprotein B core lipidation. "J. Nutr. 128, 463S- 466S;	
	Rustaeu&etal., 1998, "The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipprotein B-100 very low density lipotyctein in McA-RH7777 cells." J.Biol, Ghem 273, 5196-5203	
	Shelness and Sellers, 2001, "Very-low-density Ipoprotein assembly and secretion." Curr. Opin. Lipidol, 12(2): 151-157	
	Stillemark et al., 2000, "The assembly and secretion of apolipoprotein B- 48-containing very law density lipoprotein in McA-RH7777 cells." J. Biol. Chem. 275,10506-10313	
	Stromhaug etal., 1998, Purification and characterization of autophagosomes from rat hepatocytes." Biochem. J. 335,217-224	
	Sullivan etal., 1986, "Paradixical prevation of Idl apoprotein - b levels in hypertriglyceridemic patients and normal subjects ingesting fish oil atheroscierosis", Atheroscierosis, 61: 129-134	
	Tran et al., 1998, "Functional analysis of disulfide linkages clustered within the amino terminus of human apolloprotein B.", J. Biol. Chem 273,7244-7251	
	Tran et al., 2000, "The ssembly of very low density lipoproteins in rat hepatoma McA-RH777, cells is inhibited by phospholipase A2 antagonists.", J. Biol Chem 275, 26023-25030	
	Tran et al.,2002, Intracellular assembly of Very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells.", J. Biol. Chem. 277, 3/187-31200	
	Ueno etal., 1/91, "Membrane markers of endoplashic reticulum preserved in autophodic vacuolar membranes isolated from leuneptin-administered rat liver." 1/Biol. Chem, 266,18995-18999	
	Verkage et al., 1993, "Impaired biosynthesis of phosphatidylcholine causes a degrease in the number of very low density lipoprotein particles in the Golgi but not in the endoplasmic reticulum of rat liver." J. Biol. Chem. 368(33): 24990-24996	
	Vukmirica et al., 2002, "The N-linked oligosaccharides at the amino terminus of human apoB are important for the assembly and secretion of VLDL." J. Lipid Res. 43,1496-1507	
	Wang etal., 1995, "Degradation of apolipoprotein B in cultured rat hepatocytes occurs in a post-endoplasmic reticulum compartment." J. Biol. Chem. 270,24924-24931	
	Wang et al, 1999, "The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells. A unified model for the assembly of very low density lipoproteins." J. Biol Chem 274, 27793-27800	/
	Wong and Nestel, 1987, "Eicosapentaenoic acid inhibits the secretion of triacylglycerol and of apoprotein B and the binding of LDL in Hep G2 cells."	

Atherosclerosis 64,139-146
Yao et al., 1997, "Intracellular degradation of newly synthesized apolipoprotein B." J. Lipid Res. 38, 1937-1953
Yao and Vance, 1988, "The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes." J. Biol Chem. 263, 2998-3004
Yamamoto etal, 1990, "Characterization of the isolation membranes and the limiting membranes of autophagosomes in rat hepatocytes by ectin cytochemistry." J. Histochem. Cytochem. 38,573-580
Zhang etal., 2002, "Creating new. fluorescent probes for cell biology." Nat. Rev. Mol. Cell Biol. 3,906-918

07/21/2009 /Taevoon Kim Signature Considered SURJECTURE: Initial if reference considered, whether or not citation is in conformance with PPEP 609. Draw line through citation if not in conformance and not considered. Include, copy of this form with next communication is applicable to considered. Include, copy of this form with next communication is proposed to the proposed of the proposed in conformance and not considered. Include considered in conformance with proposed considered in conformance with perfect of the proposed considered in conformance with perfect conformation and perfect conformation and perfect conformation with perfect conformation and perfect conformation with perfect conformation and perfect conformation with perfect conformation and perfect

Date

Examiner

This collection of information is required by 37 CFR.1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including pathering, prepanging, and submitting the completed application form to the USPTO. Time will vary depending upon the individual cities. Any comments in the amount of time you require to complete this form and/or auggestons for reducing this burden, should be sele to the Chief Information Oriecr, U.S. Pattern and Trademark Office, U.S. Don't Selvo (P.D. Soz. 446.9, Assandris, N.A. 2013-1465). On the Selvo Test Sor COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patentia, 7.0. Boy, 1456, Metandris, V.A. 2231-1465.

If you need assistance in completing ti rm, call 1-800-PTO-9199 and select option 2.